- Home
- DQ vs NMRA Comparison
DQ vs NMRA Comparison
Compare DQ & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DQ
- NMRA
- Stock Information
- Founded
- DQ 2006
- NMRA 2019
- Country
- DQ China
- NMRA United States
- Employees
- DQ N/A
- NMRA N/A
- Industry
- DQ Semiconductors
- NMRA
- Sector
- DQ Technology
- NMRA
- Exchange
- DQ Nasdaq
- NMRA Nasdaq
- Market Cap
- DQ 1.4B
- NMRA 1.7B
- IPO Year
- DQ 2010
- NMRA 2023
- Fundamental
- Price
- DQ $19.07
- NMRA $2.05
- Analyst Decision
- DQ Hold
- NMRA Strong Buy
- Analyst Count
- DQ 5
- NMRA 6
- Target Price
- DQ $20.31
- NMRA $20.67
- AVG Volume (30 Days)
- DQ 798.7K
- NMRA 6.3M
- Earning Date
- DQ 02-26-2025
- NMRA 03-06-2025
- Dividend Yield
- DQ N/A
- NMRA N/A
- EPS Growth
- DQ N/A
- NMRA N/A
- EPS
- DQ N/A
- NMRA N/A
- Revenue
- DQ $1,310,019,000.00
- NMRA N/A
- Revenue This Year
- DQ N/A
- NMRA N/A
- Revenue Next Year
- DQ $49.41
- NMRA N/A
- P/E Ratio
- DQ N/A
- NMRA N/A
- Revenue Growth
- DQ N/A
- NMRA N/A
- 52 Week Low
- DQ $13.62
- NMRA $1.83
- 52 Week High
- DQ $30.85
- NMRA $21.00
- Technical
- Relative Strength Index (RSI)
- DQ 47.43
- NMRA 20.26
- Support Level
- DQ $18.52
- NMRA $2.12
- Resistance Level
- DQ $19.78
- NMRA $2.44
- Average True Range (ATR)
- DQ 1.00
- NMRA 0.39
- MACD
- DQ -0.07
- NMRA -0.31
- Stochastic Oscillator
- DQ 19.34
- NMRA 2.26
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.